Faeth Therapeutics (FTH) Non-Current Assets (2020 - 2026)
Faeth Therapeutics' (FTH) quarterly Non-Current Assets came in at -$58.8 million in Q1 2026, down 64.92% YoY from -$167.8 million in Q1 2025, and down 4318.49% on a QoQ basis from $1.4 million in Q4 2025.
Faeth Therapeutics (FTH) Non-Current Assets (2020 - 2026) Analysis & Trends
Faeth Therapeutics (FTH) has 7 years of Non-Current Assets data on file, last reported at -$58.8 million in Q1 2026.
- Quarterly Non-Current Assets fell 64.92% year-over-year to -$58.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$53.4 million (down 151.6% YoY) and the FY2025 annual result came in at $1.4 million, down 59.35% from the prior year.
- Non-Current Assets fell to -$58.8 million in Q1 2026, from $1.4 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $11.1 million in Q1 2022 to a low of -$58.8 million in Q1 2026.
- A 5-year average of $369352.9 and a median of $6.5 million in 2024 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2022 — Non-Current Assets soared 554.11% — and 2025, when it tumbled 652.27%.
- Tracing FTH's Non-Current Assets over 5 years: stood at $9.8 million in 2022, then dropped by 27.2% to $7.1 million in 2023, then slumped by 51.82% to $3.4 million in 2024, then plunged by 59.35% to $1.4 million in 2025, then plunged by 4318.49% to -$58.8 million in 2026.
- The last three Non-Current Assets figures came in at -$58.8 million (Q1 2026), $1.4 million (Q4 2025), and $1.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 938.60 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 468.65 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 18.06 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 6.80 Bn |
| 10 | Faeth Therapeutics | 180.89 Mn | 180.89 Mn | - | -43.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -43.27 Mn |
| Mar 31, 2026 | -58.85 Mn |
| Dec 31, 2025 | 1.40 Mn |
| Sep 30, 2025 | 1.80 Mn |
| Jun 30, 2025 | 2.21 Mn |
| Mar 31, 2025 | -35.68 Mn |
| Dec 31, 2024 | 3.43 Mn |
| Sep 30, 2024 | 5.16 Mn |
| Jun 30, 2024 | 5.86 Mn |
| Mar 31, 2024 | 6.46 Mn |
| Dec 31, 2023 | 7.12 Mn |
| Sep 30, 2023 | 7.82 Mn |
| Jun 30, 2023 | 8.51 Mn |
| Mar 31, 2023 | 9.33 Mn |
| Dec 31, 2022 | 9.79 Mn |
| Sep 30, 2022 | 10.32 Mn |
| Jun 30, 2022 | 10.55 Mn |
| Mar 31, 2022 | 11.06 Mn |
| Dec 31, 2021 | 4.68 Mn |
| Sep 30, 2021 | 3.09 Mn |